In
China, the malignant
tumor with the highest
incidence and motality is
lung cancer (LC). As
screening and early
detection and
treatment are effective in reducing LC
mortality, formulating a
guideline in line with
China′s national conditions for the
screening and early
detection and
treatment of LC
will greatly promote the homogeneity and accuracy of LC
screening, and result in an improvement of the
effectiveness of LC
screening. Commissioned and directed by the
Disease Prevention and Control Bureau of the National
Health Commission of the People′s
Republic of China, the guidline was initiated by the National
Cancer Center of
China and formulated with
joint effort by experts from different disciplines. Following the principles and
methods in
WHO Handbook for
Guideline Development, the guidline integrates the latest development in LC
screening and
early diagnosis and
treatment worldwide while fully considering
China′s national conditions and practical experience in LC
screening. It provides detailed evidence-based recommendations for different aspects of LC
screening, such as the targeted
population, the
technologies and the
procedures, to regulate the practices of LC
screening and
early diagnosis and
treatment and enhance the
effectiveness of the prevention and control of LC in
China.